Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Sage Therapeutics in a research report issued on Wednesday, April 30th. HC Wainwright analyst D. Tsao forecasts that the biopharmaceutical company will earn ($0.82) per share for the quarter. HC Wainwright has a "Neutral" rating and a $12.00 price objective on the stock. The consensus estimate for Sage Therapeutics' current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for Sage Therapeutics' Q2 2026 earnings at ($0.84) EPS, Q3 2026 earnings at ($0.68) EPS and Q4 2026 earnings at ($0.68) EPS.
Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02). The company had revenue of $14.06 million for the quarter, compared to analysts' expectations of $14.12 million. Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The company's revenue for the quarter was up 78.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.80) EPS.
SAGE has been the topic of a number of other research reports. Wedbush restated a "neutral" rating and set a $6.00 target price on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Canaccord Genuity Group decreased their price objective on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating on the stock in a report on Wednesday, February 12th. Bank of America initiated coverage on Sage Therapeutics in a research note on Tuesday, March 11th. They issued an "underperform" rating and a $5.00 target price for the company. StockNews.com upgraded Sage Therapeutics from a "sell" rating to a "hold" rating in a report on Friday. Finally, Scotiabank cut their price objective on shares of Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $8.81.
View Our Latest Stock Analysis on SAGE
Sage Therapeutics Trading Down 4.5 %
Shares of NASDAQ SAGE traded down $0.33 during midday trading on Thursday, reaching $6.85. 1,059,332 shares of the stock were exchanged, compared to its average volume of 1,218,578. The stock has a 50 day moving average price of $7.54 and a 200-day moving average price of $6.77. The company has a market capitalization of $428.64 million, a P/E ratio of -1.04 and a beta of 0.20. Sage Therapeutics has a 52-week low of $4.62 and a 52-week high of $14.31.
Hedge Funds Weigh In On Sage Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. CWM LLC lifted its holdings in Sage Therapeutics by 1,943.1% in the 1st quarter. CWM LLC now owns 61,416 shares of the biopharmaceutical company's stock worth $488,000 after buying an additional 58,410 shares in the last quarter. Cerity Partners LLC purchased a new stake in shares of Sage Therapeutics during the first quarter worth about $398,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Sage Therapeutics in the first quarter worth about $347,000. Pallas Capital Advisors LLC purchased a new position in Sage Therapeutics in the first quarter valued at about $166,000. Finally, Merit Financial Group LLC acquired a new stake in Sage Therapeutics during the 1st quarter valued at approximately $87,000. Hedge funds and other institutional investors own 99.22% of the company's stock.
About Sage Therapeutics
(
Get Free Report)
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Featured Stories
Before you consider Sage Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sage Therapeutics wasn't on the list.
While Sage Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
